Drugs / SF-DEVD-2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05828238 | Jan 2023 → Jan 2024 | breast cancer | Affiliated Hospital of Jiangnan University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SF-DEVD-2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05828238 ↗ |
| Known as | [18F]SF-DEVD-2 | “Drug: [18F]SF-DEVD-2” NCT05828238 ↗ |
| Modality | Diagnostic / imaging agent | “apoptotic molecular probe SF-DEVD-2” NCT05828238 ↗ |